Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
– Funds will be used to establish clinical proof of concept for Artiva’s CAR-NK and universal NK cell therapies– Artiva has exclusive access to a proprietary large-scale NK cell manufacturing platform and infrastructure– First clinical study planned for later this year followed by two additional clinical programs June 26, 2020 12:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–Artiva […]
